{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T18:41:31Z","timestamp":1779907291907,"version":"3.53.1"},"reference-count":27,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Daratumumab in combination with lenalidomide and dexamethasone (DRd) and bortezomib in combination with lenalidomide and dexamethasone (VRd) are guideline\u2010recommended preferred regimens for initial treatment of transplant\u2010ineligible (TIE) patients with newly diagnosed multiple myeloma (NDMM). This study aimed to systematically identify evidence on the clinical effectiveness of DRd and VRd as first\u2010line treatments for patients with TIE NDMM and to conduct a meta\u2010analysis. Ovid MEDLINE, Embase, and Cochrane Library were searched from January 2019 to June 2023, along with key congresses from January 2018 to June 2023. Bibliographies of relevant systematic literature reviews (SLR) were hand\u2010searched. Randomized controlled trials and appropriately adjusted non\u2010randomized studies comparing DRd versus VRd as first\u2010line treatment for TIE NDMM were included. Overall, five records from three unique studies were identified. The fixed\u2010effects meta\u2010analysis showed a lower risk of disease progression or death with DRd versus VRd using the na\u00efve approach (hazard ratio [HR]: 0.60; 95% confidence interval [CI]: 0.46, 0.77) as well as with the adjusted approach, which accounted for both double counting (i.e., two studies shared one comparison) and variance inflation due to studies with moderate and high risk of bias (HR: 0.56; 95% CI: 0.39, 0.82). In the absence of clinical trials with head\u2010to\u2010head comparison of these treatment regimens, these results could help inform the selection of optimal first\u2010line treatment for TIE NDMM patients.<\/jats:p>","DOI":"10.1002\/hon.70061","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T07:39:06Z","timestamp":1744270746000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Daratumumab, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide, and Dexamethasone in Transplant\u2010Ineligible Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Meta\u2010Analysis"],"prefix":"10.1002","volume":"43","author":[{"given":"Lucio N.","family":"Gordan","sequence":"first","affiliation":[{"name":"Florida Cancer Specialists &amp; Research Institute  Gainesville Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6422-2080","authenticated-orcid":false,"given":"Rohan","family":"Medhekar","sequence":"additional","affiliation":[{"name":"Real World Value and Evidence Oncology Janssen Scientific Affairs LLC  Horsham Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex Z.","family":"Fu","sequence":"additional","affiliation":[{"name":"Real World Analytics Janssen Scientific Affairs LLC  Titusville New Jersey USA"},{"name":"Georgetown University Medical Center  Washington District of Columbia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa","family":"Shokoohi","sequence":"additional","affiliation":[{"name":"Value &amp; Evidence Division Marketing and Market Access EVERSANA  Burlington Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abril","family":"Oliva Ramirez","sequence":"additional","affiliation":[{"name":"Value &amp; Evidence Division Marketing and Market Access EVERSANA  Burlington Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolle","family":"Bonar","sequence":"additional","affiliation":[{"name":"Value &amp; Evidence Division Marketing and Market Access EVERSANA  Burlington Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6026-2270","authenticated-orcid":false,"given":"Bao\u2010Ngoc","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Value &amp; Evidence Division Marketing and Market Access EVERSANA  Burlington Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Spence","sequence":"additional","affiliation":[{"name":"Value &amp; Evidence Division Marketing and Market Access EVERSANA  Burlington Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"McTavish","sequence":"additional","affiliation":[{"name":"Value &amp; Evidence Division Marketing and Market Access EVERSANA  Burlington Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Disher","sequence":"additional","affiliation":[{"name":"Value &amp; Evidence Division Marketing and Market Access EVERSANA  Burlington Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Gautam","sequence":"additional","affiliation":[{"name":"Real World Value and Evidence Oncology Janssen Scientific Affairs LLC  Horsham Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niodita","family":"Gupta\u2010Werner","sequence":"additional","affiliation":[{"name":"Real World Value and Evidence Oncology Janssen Scientific Affairs LLC  Horsham Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuchita","family":"Kaila","sequence":"additional","affiliation":[{"name":"Real World Value and Evidence Oncology Janssen Scientific Affairs LLC  Horsham Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjan J.","family":"Patel","sequence":"additional","affiliation":[{"name":"Florida Cancer Specialists &amp; Research Institute  Gainesville Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/medsci9010003"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2015.06.003"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2007.08.006"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2015.11.007"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx096"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation\u20102017.1.498"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817249"},{"key":"e_1_2_11_9_1","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Multiple Myeloma Version 2 \u00a9 National Comprehensive Cancer Network Inc. 2023. All Rights Reserved. To view the most recent and complete version of the guidelines go online to NCCN.org. NCCN makes no warranties or any kind whatsoever regarding their content use or application and disclaims any responsibility for their application or use in any way (2024). Accessed November 20 2023."},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3041"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103504"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1683736"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.206912"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325\u2010022\u201002083\u20108"},{"key":"e_1_2_11_15_1","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.2","author":"Higgins J. P. T. T. J.","year":"2021"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2021.02.003"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2016.01.021"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13554"},{"key":"e_1_2_11_20_1","unstructured":"U.S. Food and Drug Administration FDA Approves Daratumumab for Multiple Myeloma Ineligible for Autologous Stem Cell Transplant (2019)."},{"key":"e_1_2_11_21_1","unstructured":"National Institute for Health and Care Excellence (NICE) Single Technology Appraisal and Highly Specialised Technologies Evaluation: User Guide for Company Evidence Submission Template Process and Methods [PMG24]."},{"key":"e_1_2_11_22_1","first-page":"355","article-title":"ROBINS\u2010I: A Tool for Assessing Risk of Bias in Non\u2010Randomised Studies of Interventions","author":"Sterne J. A.","year":"2016","journal-title":"BMJ"},{"key":"e_1_2_11_23_1","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins J.","year":"2022"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.7223"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/ebmental\u20102019\u2010300117"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25963"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.09.003"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325\u2010024\u201002807\u2010y"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.70061","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hon.70061","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.70061","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T09:26:05Z","timestamp":1772961965000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.70061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1002\/hon.70061"],"URL":"https:\/\/doi.org\/10.1002\/hon.70061","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,10]]},"assertion":[{"value":"2024-09-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70061"}}